Clinical study of oral administration of DN-1417, a TRH analog, in patients with intractable epilepsy.
An open dose-finding trial of orally administered DN-1417 was undertaken to investigate dose, efficacy, and adverse reactions. One hundred ninety patients, with epilepsy resistant to conventional drug treatment, were randomly allocated to two treatment groups of low dose (20 mg/day for adult) and high dose (80 mg/day for adult). Medication was given while fasting, once a day, for 8 weeks. If at the end of the first 4-week treatment period the patient had a satisfactory response, the dose was doubled. Patient response was assessed by global improvement rating (GIR) based on changes in seizure frequency, EEG findings, and nonparoxysmal clinical manifestations. The responses assessed by GIR was "slightly to markedly improved" in 48% of the patients with low-dose treatment and 55% with high-dose treatment. There was no clear dose-related difference between the two treatments. In patients with Lennox-Gastaut syndrome having no history of West syndrome, the rate of response assessed by GIR was found to be slightly dose-related (low dose, 61%; high dose, 73%).
Inanaga
K
K
Department of Neuropsychiatry, Kurume University School of Medicine, Japan.
Kumashiro
H
H
Fukuyama
Y
Y
Ohtahara
S
S
Shirouzu
M
M
D000284:Administration, Oral; D000328:Adult; D000927:Anticonvulsants / Q000008:administration & dosage*; D002648:Child; D002986:Clinical Trials as Topic; D004828:Epilepsies, Partial / Q000188:drug therapy; D004827:Epilepsy / Q000188:drug therapy*; D005500:Follow-Up Studies; D006728:Hormones / Q000008:administration & dosage*; D006801:Humans; D011897:Random Allocation; D013973:Thyrotropin-Releasing Hormone / Q000008:administration & dosage / Q000031:analogs & derivatives*; D013997:Time Factors
D000927:Anticonvulsants; D006728:Hormones; D013973:Thyrotropin-Releasing Hormone; C029762:DN 1417